Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

References

Page 1

	Year	Citations
MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY Donald L. Lamm, Brent A. Blumenstein, John D. Crissman, The Journal of Urology	2000	1.3K
Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer Donald L. Lamm, A.P.M. van der Meijden, Álvaro Morales, The Journal of Urology	1992	783
A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder Donald L. Lamm, Brent A. Blumenstein, E. David Crawford, New England Journal of Medicine	1991	613
A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. Adam Pawinski, Richard Sylvester, K. H. Kurth, PubMed	1996	264
A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer Adam Pawinski, Richard Sylvester, K. H. Kurth, The Journal of Urology	1996	244
INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL Adrian P.M. van der Meijden, Maurizio Brausi, Victor Zambon, The Journal of Urology	2001	139
Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer Fabien Saint, Jacques Irani, Jean Jacques Patard, Urology Urological ResearchUrologySurgical OncologyVoiding DysfunctionGenitourinary Cancer	2001	96
Does Isoniazid Reduce Side Effects of Intravesical Bacillus Calmette-Guerin Therapy in Superficial Bladder Cancer? Interim Results of European Organization for Research and Treatment of Cancer Protocol 30911 P. D. J. Vegt, Adrian P.M. van der Meijden, Richard Sylvester, The Journal of Urology	1997	90
Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Lamm Dl, A Steg, L Boccon-Gibod, PubMed Bacillus Calmette-guerin ImmunotherapyPathologyInfection ControlImmunotherapyMedicine	1989	89
Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and Compliance Giuseppe Morgia, Mario Falsaperla, Massimo Madonia, UroOncology Surgical OncologyCancer ManagementImmunotherapeuticsPharmacotherapyImmunotherapy	2003	14

Page 1